Meeting
2015 ASCO Annual Meeting
The role of salvage radiation in recurrent glioblastoma after bevacizumab failure.
Authors
Nehaw Sarmey
Cleveland Clinic, Cleveland Heights, OH
Nehaw Sarmey , Samuel T. Chao , Erin Sennett Murphy , Jennifer S. Yu , David M. Peereboom , Glen Stevens , John H. Suh , Manmeet Singh Ahluwalia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2048)
DOI
10.1200/jco.2015.33.15_suppl.2048
Abstract #
2048
Poster Bd #
37
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.
First Author: Wolfgang Wick
Poster
2016 ASCO Annual Meeting
Blood baseline neutrophil count to predict bevacizumab efficacy in glioblastoma.
First Author: Aurelie Bertaut
Poster
2016 ASCO Annual Meeting
Overall survival in patients with glioblastoma before and after bevacizumab approval.
First Author: Derek Richard Johnson
Poster
2023 ASCO Annual Meeting
Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).
First Author: Samuel Aaron Goldlust